Proteomics International Laboratories

Proteomics International Laboratories FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Proteomics International Laboratories (PIQ.AX) as of Nov 4, 2026 is 92.09 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 81.75 % — a change of 12.64% (higher).

FCF Conversion

92.09 %

YoY

12.64%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Proteomics International Laboratories is 2026 92.09 % . FCF Conversion Rate (FCF/EBITDA) of Proteomics International Laboratories was 2025 81.75 % . It decreases by 12.64% higher compared to the previous year.

The Proteomics International Laboratories FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
81.96 AUD
Jan 1, 2020
113.01 AUD
Jan 1, 2021
84.42 AUD
Jan 1, 2022
73.79 AUD
Jan 1, 2023
110.85 AUD
Jan 1, 2024
94.04 AUD
Jan 1, 2025
81.75 AUD
Jan 1, 2026
92.09 AUD
The Proteomics International Laboratories FCF Conversion history
YEARFCF ConversionYoY
92.09 %+12.64%
81.75 %-13.07%
94.04 %-15.16%
110.85 %+50.23%
73.79 %-12.60%
84.42 %-25.30%
113.01 %+37.88%
81.96 %+4.05%
78.77 %-55.38%
176.53 %+53.94%
114.67 %+90.61%
60.16 %-56.36%
137.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Proteomics International Laboratories Stock analysis

What does Proteomics International Laboratories do? Proteomics International Laboratories Ltd is a medical technology company based in Nedlands, Western Australia, listed on the stock exchange in April 2015. Operating within the health care sector, the firm specializes in predictive diagnostics and bio-analytical services, focusing on the study of protein structure and function. It develops and commercializes diagnostic tests for chronic diseases, particularly diabetic kidney disease. The company operates three unified business units: PromarkerD, which offers a blood test to assess DKD risk in type 2 diabetes patients; Diagnostics, which utilizes the Promarker platform to discover and validate protein biomarkers; and Analytical Services, which employs a proteomics-based technology platform to test and validate the protein composition of various products. Proteomics International Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proteomics International Laboratories stock

FCF Conversion Rate (FCF/EBITDA) of Proteomics International Laboratories is 92.09 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Proteomics International Laboratories changed from 81.75 % to 92.09 %, representing a 12.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Proteomics International Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Proteomics International Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Proteomics International Laboratories

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Proteomics International Laboratories